RxSight Plunges 19.6% on Missed Revenue, Guidance Cut

On April 3, 2025, RxSight's stock experienced a significant drop of 19.6% in pre-market trading, reflecting investor concerns over the company's recent financial performance and revised guidance.

RxSight reported preliminary first-quarter 2025 revenue of $37.9 million, which, while representing a 28% year-over-year growth, fell short of the consensus estimate of $47.0 million. This discrepancy has raised questions about the company's ability to meet market expectations and sustain its growth trajectory.

In addition to the revenue shortfall, RxSight revised its full-year 2025 guidance, lowering its revenue projection to a range of $160 million to $175 million from the previous estimate of $185 million. This downward revision has further dampened investor sentiment, contributing to the stock's decline.

Despite the 28% growth in Q1 revenue, the company's performance has been overshadowed by the significant gap between its reported revenue and market expectations. This has led to a reassessment of RxSight's valuation and growth prospects, with investors expressing caution about the company's future performance.